Time-series RNA-seq reads of MDA-MB-231 cells treated with 100nM doxorubicin
MDA-MB-231 breast cancer cells were treated with 100 nM doxorubicin for 24h and observed over time in order to elucidate the biological processes of phenotypical adaptation involved in chemoresistance development and identify potential novel targets for future combination therapies.